Ashok Arasu, P. Balakrishnan, T. Velusamy, T. Ramesh
{"title":"Can Mandated BCG Vaccine Promote herd Immunity against Novel Coronavirus? A Potential Solution at Hand to Tackle Covid-19 Pandemic","authors":"Ashok Arasu, P. Balakrishnan, T. Velusamy, T. Ramesh","doi":"10.2174/1573395516999201112092557","DOIUrl":null,"url":null,"abstract":"\n\nThe 2019 novel coronavirus (2019-nCoV) infection is an emerging pandemic that poses\na severe threat to global public health. This pandemic started from the Wuhan City of Hubei\nProvince in China, and is speculated to have originated from bats and spread among humans with\nan unknown intermediate transmitter. The virus binds to angiotensin-converting enzyme 2 (ACE2),\nwhich is abundantly expressed on various human cells, including lung epithelial and intestinal\ncells, thereby entering into these cells and causing infection. It is transmitted to other humans\nthrough airborne droplets from infected patients. Presently there are no specific treatments or\nvaccines that are available to curtail the spread of this disease. There are few indirect reports that\nexplain the potential importance of the mandated BCG vaccine as a protective factor against\nCOVID-19. There is a speculation that a live attenuated vaccine (BCG vaccine) can be beneficial\nagainst COVID-19 to develop the initial immune response, and can also spread in the community,\nthereby boosting herd immunity to fight against COVID-19. This review summarizes the conclusions\nof various reports on the BCG vaccine, and is an attempt to establish BCG-vaccination mediated\nherd immunity as an effective instant intermediate approach in curbing COVID-19 spread in\nhighly populous countries.\n","PeriodicalId":35403,"journal":{"name":"Current Immunology Reviews","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Immunology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573395516999201112092557","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2
Abstract
The 2019 novel coronavirus (2019-nCoV) infection is an emerging pandemic that poses
a severe threat to global public health. This pandemic started from the Wuhan City of Hubei
Province in China, and is speculated to have originated from bats and spread among humans with
an unknown intermediate transmitter. The virus binds to angiotensin-converting enzyme 2 (ACE2),
which is abundantly expressed on various human cells, including lung epithelial and intestinal
cells, thereby entering into these cells and causing infection. It is transmitted to other humans
through airborne droplets from infected patients. Presently there are no specific treatments or
vaccines that are available to curtail the spread of this disease. There are few indirect reports that
explain the potential importance of the mandated BCG vaccine as a protective factor against
COVID-19. There is a speculation that a live attenuated vaccine (BCG vaccine) can be beneficial
against COVID-19 to develop the initial immune response, and can also spread in the community,
thereby boosting herd immunity to fight against COVID-19. This review summarizes the conclusions
of various reports on the BCG vaccine, and is an attempt to establish BCG-vaccination mediated
herd immunity as an effective instant intermediate approach in curbing COVID-19 spread in
highly populous countries.
期刊介绍:
Current Immunology Reviews publishes frontier reviews on all the latest advances in clinical immunology. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in clinical immunology.